Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease
Abstract Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies. However, decreased patient acceptance...
Saved in:
Main Authors: | Kerry A. Ryan (Author), Shirley Cohen-Mekelburg (Author), Jessica A. Baker (Author), Eileen M. Weinheimer-Haus (Author), Chris Krenz (Author), Jason K. Hou (Author), Raymond De Vries (Author), Akbar K. Waljee (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eliciting patient views on the allocation of limited healthcare resources: a deliberation on hepatitis C treatment in the Veterans Health Administration
by: Akbar K. Waljee, et al.
Published: (2020) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022) -
Switching Among Biosimilars: A Review of Clinical Evidence
by: Eleonora Allocati, et al.
Published: (2022) -
The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
by: Claudia Fabiani, et al.
Published: (2019) -
Implementing a Medication Switching Policy: Analysis of the Saskatchewan Biosimilars Initiative
by: Kirsten Fox
Published: (2024)